Use was evaluated in a 16 week double-masked, randomized, vehicle controlled study in pediatric patients with several different conditions (post-chemotherapy, alopecia areata, and adolescents with hypotrichosis and no associated medical condition No new safety issues were observed Postmarketing study
|